Neurizon Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF), an Australia-based clinical-stage biotechnology company, announced on Thursday that it has dosed its first participant in Regimen I of the HEALEY ALS Platform Trial assessing the company's lead candidate, NUZ-001, intended for the treatment of amyotrophic lateral sclerosis (ALS).

The HEALEY ALS Platform Trial (ClinicalTrials.gov identifier: NCT04297683) is a multicentre, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial conducted by the Sean M. Healey & AMG Centre for ALS at Mass General Hospital Brigham in the United States, created in partnership with the Network of Excellence for ALS (NEALS).

The goal of the HEALEY ALS Platform Trial is to accelerate the development of potential new ALS therapies. The trial evaluates multiple investigational drugs concurrently under a single framework or master protocol, leveraging shared infrastructure across over 70 participating clinical sites. By streamlining start-up and enrolment processes, the company says it can accelerate study execution and deliver results more efficiently.